Using IVIG to treat gastrointestinal autoimmune neuropathy
IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy
This study is testing whether intravenous immunoglobulin (IVIG) can help people with autoimmune gastrointestinal issues feel better when other treatments haven't worked.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 12 Years to 90 Years |
| Sex | All |
| Sponsor | University of Louisville Academic / other |
| Locations | 1 site (Louisville, Kentucky) |
| Trial ID | NCT04208828 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients suffering from gastrointestinal motility disorders, particularly those with autoimmune findings who have not responded to standard treatments. It aims to document the clinical observations and responses of these patients to intravenous immunoglobulin (IVIG) therapy. Patients will complete standardized surveys to assess their gastrointestinal symptoms before and after receiving IVIG. The study seeks to identify the effectiveness of IVIG in managing symptoms of autoimmune gastrointestinal neuropathies.
Who should consider this trial
Good fit: Ideal candidates are patients with refractory gastrointestinal motor disorders who may have autoimmune components.
Not a fit: Patients who are unable to receive intravenous immunoglobulin will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for patients with refractory gastrointestinal motility disorders.
How similar studies have performed: Other studies have shown promising results with IVIG therapy in similar autoimmune conditions, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patient with otherwise refractory symptoms of gastrointestinal (GI) motor disorders. \- Exclusion Criteria: Inability to receive intravenous immunoglobulin. \-
Where this trial is running
Louisville, Kentucky
- University of Louisville — Louisville, Kentucky, United States (Recruiting)
Study contacts
- Study coordinator: Thomas L Abell, MD
- Email: thomas.abell@louisville.edu
- Phone: (502)852-6991
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.